These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus. Patschan S; Dolff S; Kribben A; Dürig J; Patschan D; Wilde B; Specker C; Philipp T; Witzke O Clin Exp Immunol; 2006 Aug; 145(2):235-42. PubMed ID: 16879242 [TBL] [Abstract][Full Text] [Related]
49. Recent advances in understanding pathogenesis and therapeutic strategies of Systemic Lupus Erythematosus. Luo S; Long H; Lu Q Int Immunopharmacol; 2020 Dec; 89(Pt A):107028. PubMed ID: 33039962 [TBL] [Abstract][Full Text] [Related]
51. Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study. Hu SC; Yen FL; Wang TN; Lin YC; Lin CL; Chen GS J Am Acad Dermatol; 2016 Jul; 75(1):49-58. PubMed ID: 26946984 [TBL] [Abstract][Full Text] [Related]
52. Azathioprine therapy for patients with systemic lupus erythematosus. Abu-Shakra M; Shoenfeld Y Lupus; 2001; 10(3):152-3. PubMed ID: 11315344 [TBL] [Abstract][Full Text] [Related]
53. Non-erythropoietic erythropoietin-derived peptide protects mice from systemic lupus erythematosus. Huang B; Jiang J; Luo B; Zhu W; Liu Y; Wang Z; Zhang Z J Cell Mol Med; 2018 Jul; 22(7):3330-3339. PubMed ID: 29570934 [TBL] [Abstract][Full Text] [Related]
54. Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa. Lewandowski LB; Schanberg LE; Thielman N; Phuti A; Kalla AA; Okpechi I; Nourse P; Gajjar P; Faller G; Ambaram P; Reuter H; Spittal G; Scott C Lupus; 2017 Feb; 26(2):186-194. PubMed ID: 27488473 [TBL] [Abstract][Full Text] [Related]
55. Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus. Ren J; Catalina MD; Eden K; Liao X; Read KA; Luo X; McMillan RP; Hulver MW; Jarpe M; Bachali P; Grammer AC; Lipsky PE; Reilly CM Front Immunol; 2019; 10():2512. PubMed ID: 31708928 [TBL] [Abstract][Full Text] [Related]
56. [Progress and perspectives in the treatment of systemic lupus erythematosus]. Robak E; Sysa-Jedrzejowska A; Wozniacka A Przegl Lek; 2005; 62(9):894-9. PubMed ID: 16541725 [TBL] [Abstract][Full Text] [Related]
57. The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus. Liu Y; Ye J; Shin Ogawa L; Inoue T; Huang Q; Chu J; Bates RC; Ying W; Sonderfan AJ; Rao PE; Zhou D PLoS One; 2015; 10(5):e0127361. PubMed ID: 25974040 [TBL] [Abstract][Full Text] [Related]
58. Secondary angle-closure glaucoma as an ocular presentation of systemic lupus erythematosus: a case report. Hou X; Pan W; Wang A; Yu T; Song A J Int Med Res; 2020 Sep; 48(9):300060520959492. PubMed ID: 32996806 [TBL] [Abstract][Full Text] [Related]